

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.

Serial No.: 09/360,242

Filed: July 22, 1999

For: *METHODS AND COMPOSITIONS  
FOR TREATING SECONDARY  
TISSUE DAMAGE AND OTHER  
INFLAMMATORY CONDITIONS  
AND DISORDERS*

Art Unit: 1646

RECEIVED  
JUL 23 1999  
TECHNICAL SERVICES

INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH  
37 C.F.R. §§ 1.97-1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Since this Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 08-1641.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (27 pages) and copies of the cited documents are provided herewith.

The cited documents listed on the Forms PTO-1449 are supplied herewith in the English language, with the exception of items DI and DN. Items DI (WO

**U.S.S.N. 09/360,242**  
**MCDONALD et al.**  
**Information Disclosure Statement**

92/09629) and DN (WO 93/24620) are in the French and Spanish languages, respectively, and the English language abstracts for them may be found in their title pages. Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner that the above-captioned application is a continuation-in-part of U.S. application Serial No. 09/120,523, which was converted to a provisional application, and International PCT application No. PCT/CA99/00659, which is pending.


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

U.S.S.N. 09/360,242  
MCDONALD et al.  
Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing references and that they be made of record in the file history of the above-captioned application.

\* \* \*

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE

By:   
Stephanie L. Seidman  
Registration No. 33,779

Date: November 3, 1999  
Attorney Docket No. 25020-601B  
**Address all correspondence to:**  
Stephanie L. Seidman, Esq.  
HELLER, EHRMAN, WHITE & McAULIFFE  
4250 Executive Square, 7th Floor  
La Jolla, California 92037-9103  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.  
Serial No.: 09/360,242  
Filed: July 22, 1999  
For: *METHODS AND COMPOSITIONS  
FOR TREATING SECONDARY  
TISSUE DAMAGE AND OTHER  
INFLAMMATORY CONDITIONS  
AND DISORDERS*  
Art Unit: 1646

TRANSMITTAL LETTER


Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are an Information Disclosure Statement, Forms PTO-1449 (27 pages) and cited references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account Number 08-1641, as stated below:

( X ) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 08-1641. A duplicate of this sheet is enclosed.

Respectfully submitted  
HELLER, EHRMAN, WHITE & McAULIFFE

By:   
Stephanie L. Seidman  
Registration No. 33,779

Date: November 3, 1999  
Attorney Docket No.: 25020-601B  
Address all correspondence to:  
HELLER, EHRMAN, WHITE & McAULIFFE  
4250 Executive Square, 7th Floor  
La Jolla, California 92037-9103  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
EMAIL: sseidman@hewm.com